HOME
login
history
all enzymes
BRENDA home
History
Information on EC 2.4.1.80 - ceramide glucosyltransferase
for references in articles please use BRENDA:EC2.4.1.80Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.4.1.80 ceramide glucosyltransferaseIUBMB Comments
Sphingosine and dihydrosphingosine can also act as acceptors; CDP-glucose can act as donor.
Specify your search results
Word Map
- 2.4.1.80
- glucosylceramide
- sphingolipids
- gangliosides
- gm3
-
sphingoid
- galactosylceramide
- d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
- gaucher
- medicine
- glucocerebroside
-
nb-dnj
-
conduritol
- 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
-
udp-galactose:ceramide
- n-butyldeoxynojirimycin
-
galcers
- cgalt
-
laccer
-
d-pdmp
- pharmacology
- molecular biology
- drug development
The enzyme appears in viruses and cellular organisms
Reaction Schemes
Synonyms
ceramide glucosyltransferase, ceramide glycosyltransferase, ceramide:UDP-glucose glucosyltransferase, ceramide:UDPGlc glucosyltransferase, cerebroside synthase, CGT, cgt-1, cgt-2, cgt-3, GCS, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
ceramide glucosyltransferase
ceramide glycosyltransferase
ceramide:UDP-glucose glucosyltransferase
-
-
-
-
ceramide:UDPGlc glucosyltransferase
-
-
-
-
CGT
cgt-1
cgt-2
cgt-3
GCS
GlcCer synthase
GlcT
GlcT-1
glucosylceramide synthase
glucosyltransferase, uridine diphosphoglucose-ceramide
-
-
-
-
GluT
UDP glucose-ceramide glucosyltransferase
-
-
-
-
UDP-glucose ceramide glucosyltransferase
UDP-glucose:ceramide glucosyltransferase
Ugcg
uridine diphosphate (UDP)-glucose:N-acylsphingosine D-glucosyltransferase
-
-
uridine diphosphoglucose-ceramide glucosyltransferase
-
-
-
-
cgt-1
the Caenorhabditis elegans genome encodes three ceramide glucosyltransferase (CGT) genes
cgt-2
-
the Caenorhabditis elegans genome encodes three ceramide glucosyltransferase (CGT) genes
cgt-3
the Caenorhabditis elegans genome encodes three ceramide glucosyltransferase (CGT) genes
GCS
-
-
glucosylceramide synthase
-
-
-
-
glucosylceramide synthase
-
-
UDP-glucose:ceramide glucosyltransferase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
UDP-alpha-glucose + an N-acylsphingosine = UDP + a beta-D-glucosyl-N-acylsphingosine
UDP-glucose and inhibitor D-PDMP binding region overlap and contain His193
-
UDP-alpha-glucose + an N-acylsphingosine = UDP + a beta-D-glucosyl-N-acylsphingosine
enzyme DNA sequence contains conserved D1,D2,D3,QXXRW motif found also in other progressive beta-glycosyltransferases, putative active site, Cys207 and His193 involved; UDP-glucose and inhibitor D-PDMP binding region overlap and contain His193
-
UDP-alpha-glucose + an N-acylsphingosine = UDP + a beta-D-glucosyl-N-acylsphingosine
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hexosyl group transfer
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
UDP-glucose:N-acylsphingosine D-glucosyltransferase
Sphingosine and dihydrosphingosine can also act as acceptors; CDP-glucose can act as donor.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
37237-44-8
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
CDP-glucose + N-acylsphingosine
CDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
TDP-glucose + N-acylsphingosine
TDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP + N-{6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoyl}sphingosine
UDP + ?
-
-
-
-
?
UDP-glucose + 6-(((N-7-nitrobenz-2-oxa-1,3-diazol-4yl)amino)caproyl)sphingosine
UDP + ?
-
-
-
-
?
UDP-glucose + 6-([(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl)sphingosine
UDP + N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
UDP-glucose + an N-acylsphingosine
UDP + a D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + C6-ceramide
UDP + C6-glucosylceramide
-
with fluorescent NBD C6-ceramide resulting in NBD C6-glucosylceramide direct quantification of ceramide glycosylation catalyzed by GCS in cells and in tissues are possible
-
-
?
UDP-glucose + dihydroceramide
UDP + D-glucosyl-dihydroceramide
-
mono-, tri-, and tetrahexosylceramides, the parasite enzyme is only active on the saturated substrate
product analysis
-
?
UDP-glucose + N-(epsilon-7-nitrobenz-2-oxa-1,3-diazol-4-yl-aminocaproyl)-D-erythro-sphingosine
?
-
-
-
-
?
UDP-glucose + N-6-[(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino]hexanoyl-4-D-erythro-sphingosine
UDP + N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
-
-
-
-
?
UDP-glucose + N-acylsphinganine
UDP + D-glucosyl-N-acylsphingosine
-
stereospecific and dependent on nature and chain length of N-acylsphinganine substrate
-
?
UDP-glucose + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP + D-glucosyl-N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP-glucose + 6-([(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl)sphingosine
UDP + N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
-
synthetic fluorescent substrate in liposomes for assay method development
-
-
?
UDP-glucose + 6-([(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl)sphingosine
UDP + N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
-
synthetic fluorescent substrate in liposomes for assay method development
-
-
?
UDP-glucose + 6-([(N-7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl)sphingosine
UDP + N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
-
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
key enzyme in the synthesis of major glycosphingolipids in vertebrates
glucosylceramide is the core structure of major glycosphingolipids
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
key enzyme in the synthesis of major glycosphingolipids in vertebrates
glucosylceramide is the core structure of major glycosphingolipids
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
glucosylceramide is the core structure of major glycosphingolipids
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
ceramide and its metabolites are important mediators of apoptosis and cell survival
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
glucosylceramide is a precursor for synthesis of a multitude of higher sphingolipids
-
?
UDP-glucose + dihydrosphingosine
UDP + D-glucosyl-dihydrosphingosine
-
-
-
?
UDP-glucose + dihydrosphingosine
UDP + D-glucosyl-dihydrosphingosine
-
dihydrosphingosine is no substrate
-
-
-
UDP-glucose + dihydrosphingosine
UDP + D-glucosyl-dihydrosphingosine
-
dihydrosphingosine is no substrate
-
-
-
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
Q58FH5
GCS is a key regulator of pathogenicity of Cryptococcus neoformans by ensuring cell cycle progression and growth of fungal cells in environments characterized by neutral/alkaline pH and physiological concentrations of CO2. Since these environments are characteristically found in the lung alveolar spaces, GCS regulates survival of Cryptococcus neoformans upon inhalation through the respiratory tract, with important implications for the dissemination of fungal cells to the brain and the development of meningo-encephalitis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
Q58FH5
Cryptococcus neoformans Gcs1 expressed in Saccharomyces cerevisiae is unable to recognize 7-nitro-2-1,3-benzoxadiazol-4-yl-ceramide analogs as substrates
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
specific for UDP-glucose
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
acceptor substrate specificity, overview
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
overview: short-chain ceramide substrates
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
regulation of intracellular ceramide is closely related to drug resistance and DOX-induced apoptosis
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme is involved in renal growth, neuronal differentiation, the establishment of the water permeability barrier in keratinocytes, and multidrug resistance in cancer cell
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
first step in synthesis of gangliosides
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
key step in biosynthesis of glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
acceptor substrate specificity, overview
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
overview: short-chain ceramide substrates
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme is required for normal permeability barrier homeostasis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in the biosynthesis of glucosylceramide-based glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the enzyme catalyzes a necessary step in the conversion of ceramide to glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the enzyme catalyzes the initial step of glycosphingolipid biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the transient formation of glucosylceramide is vital for a regular arrangement of lipids and proteins in lamellar bodies and for the maintenance of the epidermal barrier
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
Ugcg-deficient mice die between postnatal day 11 and postnatal day 24. Glycosphingolipids are required for brain maturation after birth
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
key step in biosynthesis of glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
specific for ceramide substrate with trihydroxy sphingoside bases, ceramides with dihydroxy sphingoside bases are inactive, overview
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
acceptor substrate specificity, overview
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
stereospecific and dependent on nature and chain length of N-acylsphingosine substrate
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
UDP-glucose is the preferred donor substrate
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
-
-
-
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
i.e. ceramide
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-octanoyl sphingosine
UDP + D-glucosyl-N-octanoyl sphingosine
-
best substrate
-
?
UDP-glucose + N-octanoyl sphingosine
UDP + D-glucosyl-N-octanoyl sphingosine
-
best substrate
-
?
UDP-glucose + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP + D-glucosyl-N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
-
synthetic fluorescent ceramide substrate analogue for fluorescence enzyme assay
-
-
?
UDP-glucose + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP + D-glucosyl-N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
synthetic fluorescent ceramide substrate analogue for fluorescence enzyme assay
-
-
?
UDP-glucose + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP + D-glucosyl-N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
-
synthetic fluorescent ceramide substrate analogue for fluorescence enzyme assay
-
-
?
UDP-glucose + N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
UDP + D-glucosyl-N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine
-
synthetic fluorescent ceramide substrate analogue for fluorescence enzyme assay
-
-
?
additional information
?
-
-
the enzyme has dual function as negative regulator of cell death mediated by proapoptotic factors and in catalyzing the formation of glucosylceramide, the core structure of major glycosphingolipids, ceramide generation might be a signal pathway
-
-
-
additional information
?
-
-
octanoyl dihydrosphingosine, decanoyl sphingosine, and stearoyl sphingosine are poor substrates
-
-
-
additional information
?
-
-
enzyme decreases apoptosis and induces multidrug resistance, functional interaction with RTN-1C modulates enzyme activity and regulates chemotherapeutic-induced apoptosis in neuroepithelioma cells
-
-
-
additional information
?
-
-
lipid profile of the parasite at different developmental stages, overview
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
UDP-glucose + an N-acylsphingosine
UDP + a D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
key enzyme in the synthesis of major glycosphingolipids in vertebrates
glucosylceramide is the core structure of major glycosphingolipids
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
key enzyme in the synthesis of major glycosphingolipids in vertebrates
glucosylceramide is the core structure of major glycosphingolipids
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
ceramide and its metabolites are important mediators of apoptosis and cell survival
-
-
?
UDP-glucose + ceramide
UDP + glucosylceramide
-
-
glucosylceramide is a precursor for synthesis of a multitude of higher sphingolipids
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
Q58FH5
GCS is a key regulator of pathogenicity of Cryptococcus neoformans by ensuring cell cycle progression and growth of fungal cells in environments characterized by neutral/alkaline pH and physiological concentrations of CO2. Since these environments are characteristically found in the lung alveolar spaces, GCS regulates survival of Cryptococcus neoformans upon inhalation through the respiratory tract, with important implications for the dissemination of fungal cells to the brain and the development of meningo-encephalitis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
regulation of intracellular ceramide is closely related to drug resistance and DOX-induced apoptosis
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme is involved in renal growth, neuronal differentiation, the establishment of the water permeability barrier in keratinocytes, and multidrug resistance in cancer cell
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
Q16739
first step in synthesis of gangliosides
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
key step in biosynthesis of glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme is required for normal permeability barrier homeostasis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in the biosynthesis of glucosylceramide-based glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the enzyme catalyzes a necessary step in the conversion of ceramide to glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the enzyme catalyzes the initial step of glycosphingolipid biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
the transient formation of glucosylceramide is vital for a regular arrangement of lipids and proteins in lamellar bodies and for the maintenance of the epidermal barrier
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
key step in biosynthesis of glycosphingolipids
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
ceramide plays an important role in signal transduction, regulation, and cell homeostasis, thus its glycosylation may play a role in regulation of the cellular level of the bioactive lipid
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
-
-
-
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
initial key enzyme in glycosphingolipid biosynthesis
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
enzyme activity is regulated developmentally
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
-
i.e. glucosylceramide
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
catalyzes the first step during the sequential addition of carbohydrate moieties for ganglioside biosynthesis
-
-
?
UDP-glucose + N-acylsphingosine
UDP + D-glucosyl-N-acylsphingosine
-
first step in synthesis of gangliosides
-
-
?
additional information
?
-
-
the enzyme has dual function as negative regulator of cell death mediated by proapoptotic factors and in catalyzing the formation of glucosylceramide, the core structure of major glycosphingolipids, ceramide generation might be a signal pathway
-
-
-
additional information
?
-
-
enzyme decreases apoptosis and induces multidrug resistance, functional interaction with RTN-1C modulates enzyme activity and regulates chemotherapeutic-induced apoptosis in neuroepithelioma cells
-
-
-
additional information
?
-
-
lipid profile of the parasite at different developmental stages, overview
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Ca2+
Mg2+
Mn2+
additional information
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
i.e. miglitol
(2R,3R,4R,5S)-1-(5-[[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(2-fluoropyridin-4-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(2H-1,3-benzodioxol-5-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-(5-[[4-(6-fluoropyridin-3-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
-
i.e. miglustat or Zavesca
(2R,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-(hexyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-([(3R,10S,13S,17R)-10,13-dimethyl-17-[(2S)-7-methyloctan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(1R)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(1S)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(2'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(2-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(3'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(3-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(4'-chloro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(4'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(4,8-dihydropyren-1-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[(5,8-dihydronaphthalen-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-3-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-((adamantylmethoxy)hexyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-(adamantylmethoxy)pentyl)piperidine-3,4,5-triol
-
i.e. AMP-DNM
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(2,3,4,5-tetrahydro-1,6-benzodioxocin-8-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-3-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-4-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyrimidin-5-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(6-(adamantylhexyl)hexyl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(adamantylhept-6-en-1-yl)piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5-phenylpyridin-2-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(phenanthren-9-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-(hexyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-([(3R,10S,13S,17R)-10,13-dimethyl-17-[(2S)-7-methyloctan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-trio
-
-
(2S,3R,4R,5S)-1-[5-[(1R)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(1S)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(2-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(3-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(4,8-dihydropyren-1-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[(5,8-dihydronaphthalen-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-3-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-(adamantylmethoxy)pentyl)piperidine-3,4,5-triol
-
i.e. ido-AMP-DNM
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(6-(adamantylmethoxy)hexyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(6-adamantyloxyhexyl)piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[(6Z)-7-adamantylhept-6-en-1-yl]piperidine-3,4,5-triol
-
-
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(phenanthren-9-yl)methoxy]pentyl]piperidine-3,4,5-triol
-
-
(2S,3R,4S)-2-(hydroxymethyl)-4-octylpyrrolidin-3-ol
-
0.01 mM, about 70% inhibition
(2S,3R,4S)-4-butyl-2-(hydroxymethyl)pyrrolidin-3-ol
-
0.05 mM, about 30% inhibition
(D-threo)-1-(3',4'-ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol
-
the inhibitor is abolutely specific for the recombinant human enzyme and does not affect recombinant non-human enzymes from Gossypium arboreum, Caenorhabditis elegans, Aspergillus nidulans, Candida albicans, Pichia pastoris, Ustilago maydis, or Agrobacterium tumefaciens
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-2-carbonitrile
-
-
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-3-carbonitrile
-
-
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-4-carbonitrile
-
-
arsenic trioxide
-
treatment of a human acute promyelocytic leukemia cell line (NB4) and adult T-cell leukemia/lymphoma (ATL) derived cells with arsenic trioxide induces accumulation of cytoxic levels of ceramide which results from de novo ceramide synthesis and inhibition of glucosylceramide synthase activity
D,L-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
accumulation of ceramide in the cells, higher amount in Z65 mutant than in strain K1
D,L-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol
-
enzyme inhibition in vitro and in vivo, in the latter case the compound also inhibits growth of the parasite
Detergents
-
e.g. 0.5% Triton X-100 or 0.5% sodium deoxycholate; inhibition of enzyme due to permeabilization of microsomal membrane
diethyl dicarbonate
-
i.e. DEPC; reversible by hydroxylamine, UDP-glucose protects, inhibitor acts on histidine residues, including His193, within or near UDP-glucose binding site
DL-erythro-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
-
the enzyme GCS inhibitor causes cytotoxic, antiproliferative, antiangiogenic and tumor-volume-reducing effects, modulating drug responses in cell lines both cytodestructive (as a drug sensitizer) and cytoprotective, effect on cell survival, overview. The inhibitor is not suitable to deplete cells of the neolacto glycosphingolipid series
-
DL-threo-1-phenyl-2-hexadecanoyl-amino-3-pyrrolidino-1-propanol
-
i.e. most active PDMP-type congener, specific and reversible, in vivo and in vitro
DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol
-
the enzyme GCS inhibitor causes cytotoxic, antiproliferative, antiangiogenic and tumor-volume-reducing effects, modulating drug responses in cell lines both cytodestructive (as a drug sensitizer) and cytoprotective, effect on cell survival, overview. The inhibitor is not suitable to deplete cells of the neolacto glycosphingolipid series
doxorubicin
-
i.e. DOX; increases enzyme activity in drug-sensitive cell line HL-60, but not in drug-resistant HL-60/ADR cell line; regulation of intracellular ceramide is closely related to drug resistance and DOX-induced apoptosis
ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate
-
i.e. HA14-1, a reversible small molecule Bcl-2 inhibitor that also inhibits GlcT-1 enzyme activity. HA14-1 is a competitive and mixed-type inhibitor with respect to C6-NBD-ceramide and UDP-glucose, respectively. HA-14 does not possess structural homology with the substrates UDP-glucose and ceramide. Possible binding of GlcT-1 to Bcl-2
Genz-112638
-
inhibitor is tested in a murine model of Gaucher disease (D409V/null): mice that receive drug prior to significant accumulation of substrate show reduced levels of glucosylceramide and number of Gaucher cells in the spleen, lung and liver when compared to control. Treatment of older mice that already display significant amounts of tissue glucosylceramide results in arrest of further accumulation of the substrate and appearance of additional Gaucher cells in affected organs; substrate inhibition therapy with Genz-112638 represents an approach to enzyme therapy to treat the visceral pathology in Gaucher diseases
Genz-682452
-
a mall molecule inhibitor of enzyme GCS, that can traverse the blood–brain barrier. Treating Fabry mice with Genz-682452 results in reduced tissue levels of including globotriaosylceramide and lysoglobotriaosylceramide and a delayed loss of the thermal nociceptive response. Greatest improvements are realized when the therapeutic intervention is administered to younger mice before they developed overt pathology
N-(5'-adamantan-1'-yl-methoxy)-pentyl-1-deoxynojirimycin
-
highly specific small molecule inhibitor of glucosylceramide synthase. When administered to mice and rats, it significantly reduces glycosphingolipid but not ceramide concentrations in various tissues. Treatment of ob/ob mice with the inhibitor normalizes their elevated tissue glucosylceramide levels, markedly lowers circulating glucose levels, improves oral glucose tolerance, reduced A1C, and improves insulin sensitivity in muscle and liver
N-(5'-adamantane-1'-yl-methoxy)-pentyl-1-deoxynojirimycin
-
pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity
N-adamantyl-6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
-
-
N-adamantyl-6-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]-5(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
-
-
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
-
-
Phospholipase A
-
treatment of microsomes results in loss of enzyme actvity
-
Phospholipase C
-
treatment of microsomes results in loss of enzyme actvity
-
PP55B
-
i.e. isopropylidene derivative of 5'-O-[[(2-decanoylamino-3-phenylpropylloxycarbonyl)amino]sulfonyl]uridine, 21% inhibition at 0.2 mM
threo-1-phenyl-2-decanoyl-amino-3-morpholino-1-propanol
-
inhibition at 0.005 mM
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
in vivo depletion of enzyme and accumulation of ceramide; not DL-diastereomer
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
accumulation of ceramide in the cells, higher amount in Z65 mutant than in strain K1
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
i.e. PDMP
D-threo-1-phenyl-2-(decanoylamino)-3-morpholino-1-propanol-HCl
-
His193 mutants are not inhibited; i.e. PDMP
additional information
-
induction of enzyme by inhibitors in presence of higher ceramide levels
-
additional information
-
induction of enzyme by inhibitors in presence of higher ceramide levels; no inhibition by conduritol B epoxide
-
additional information
-
identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors, synthesis of a series of D-gluco- and L-ido-configured iminosugars N-modified with a variety of hydrophobic functional groups and of a series of biphenyl-substituted iminosugars of both configurations (D-gluco and L-ido), overview. Iminosugars featuring N-pentyloxymethylaryl substituents are considerably more potent inhibitors of glucosylceramide synthase than their aliphatic counterparts. Biphenyl-substituted L-ido-configured deoxynojirimycin derivatives are selective for glucosylceramidase and the nonlysosomal glucosylceramidase
-
additional information
-
synthesis and evaluation of a variety of iminosugar-based enzyme inhibitors that differ in the nature of the N substituent but also in configuration of the piperidine iminosugar, deoxynojirimycin-type iminosugars, overview. Usage of parent compound 1-phenyl-2-decanoyl-3-morpholino-1-propanol (PDMP)
-
additional information
-
GCS enzyme inhibitors affect the expression of lactosylceramide, neolacto, ganglio, and globo series glycosphingolipids in a panel of human breast cancer cell lines using flow cytometry, a commonly applied method investigating cell-surface glycosphingolipids after enzyme inhibition, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
c-Fos
-
activity of glucosylceramide synthase is around 5fold higher in presence of high c-Fos levels, induced by nerve growth factor NGF, addition of c-Fos mRNA ASO, which specifically blocks c-Fos expression abolished the induction of glucosylceramide synthase by NGF
-
dioleoyl phosphatidylcholine
-
or other exogenous phospholipid, required for activity
L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
-
L-PDMP treatment induces a 2.4 increase in glucosylceramide
detergent
-
absolute requirement for; optimal activity obtained with a mixture of Cutsum and Triton X-100 (2:1)
-
detergent
-
activity is reduced by most of the detergents tested, only CHAPS and CHAPSO at concentration of 1% w/v stimulate
-
HSP70
-
dog heat shock protein 70 increases production of glucosylceramide to 207%
-
HSP70
-
dog heat shock protein 70 increases production of glucosylceramide to 149%
-
NADH
-
omission in assay containing Golgi vesicles leads to loss of about 90% activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Breast Neoplasms
UDP-glucose ceramide glucosyltransferase activates AKT, promoted proliferation, and doxorubicin resistance in breast cancer cells.
ceramide glucosyltransferase deficiency
Identification of a novel lethal form of autosomal recessive ichthyosis caused by UDP-glucose ceramide glucosyltransferase deficiency.
Gaucher Disease
Glucosylated cholesterol in mammalian cells and tissues: formation and degradation by multiple cellular ?-glucosidases.
Ichthyosis
Identification of a novel lethal form of autosomal recessive ichthyosis caused by UDP-glucose ceramide glucosyltransferase deficiency.
Infections
Regulation of sphingolipid and glycosphingolipid metabolism in extrahepatic tissues by endotoxin.
Lysosomal Storage Diseases
Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types?1 and 2 Gaucher disease.
Melanoma
Elisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell Death.
Melanoma, Experimental
Expression machinery of GM4: the excess amounts of GM3/GM4S synthase (ST3GAL5) are necessary for GM4 synthesis in mammalian cells.
Melanoma, Experimental
Homeostasis of cell-surface glycosphingolipid content in B16 melanoma cells. Evidence revealed by an endoglycoceramidase.
Melanoma, Experimental
Novel sterol glucosyltransferase in the animal tissue and cultured cells: Evidence that glucosylceramide as glucose donor.
Mucopolysaccharidosis III
N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice.
Neoplasms
DNA damage induces down-regulation of UDP-glucose ceramide glucosyltransferase, increases ceramide levels and triggers apoptosis in p53-deficient cancer cells.
Neoplasms
Regulation of glycosphingolipid metabolism in liver during the acute phase response.
Neoplasms
Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth.
Neuroblastoma
Effects of an inhibitor of glucosylceramide synthase on glycosphingolipid synthesis and neurite outgrowth in murine neuroblastoma cell lines.
Obesity
Neuronal expression of glucosylceramide synthase in central nervous system regulates body weight and energy homeostasis.
Parkinson Disease
Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.013 - 0.02
N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
0.013
N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
-
in absence of c-Fos
0.02
N-(6-((4-nitrobenz-2-oxa-1,3-diazol-7-yl)amino)caproyl)-O1-D-glucosyl-sphingosine
-
in presence of c-Fos
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0045
ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate
-
pH 7.5, 30°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.025
(1S)-N-butyl-1-C-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
Homo sapiens
-
-
0.00002
(2R,3R,4R,5S)-1-(5-[[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00004
(2R,3R,4R,5S)-1-(5-[[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00015
(2R,3R,4R,5S)-1-(5-[[4-(2-fluoropyridin-4-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-(5-[[4-(2H-1,3-benzodioxol-5-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00075
(2R,3R,4R,5S)-1-(5-[[4-(6-fluoropyridin-3-yl)phenyl]methoxy]pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00075
(2R,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.0005
(2R,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.001
(2R,3R,4R,5S)-1-[5-([(3R,10S,13S,17R)-10,13-dimethyl-17-[(2S)-7-methyloctan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00006
(2R,3R,4R,5S)-1-[5-[(1R)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00007
(2R,3R,4R,5S)-1-[5-[(1S)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000075
(2R,3R,4R,5S)-1-[5-[(2'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-[5-[(2-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-[5-[(3'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-[5-[(3-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-[5-[(4'-chloro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-1-[5-[(4'-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
(2R,3R,4R,5S)-1-[5-[(4,8-dihydropyren-1-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
(2R,3R,4R,5S)-1-[5-[(5,8-dihydronaphthalen-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00005
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000075
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-3-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00125
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00006
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00005
(2R,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.0003
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-((adamantylmethoxy)hexyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.0002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-(adamantylmethoxy)pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.02
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
above, pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(2,3,4,5-tetrahydro-1,6-benzodioxocin-8-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-3-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyridin-4-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[4-(pyrimidin-5-yl)phenyl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.0003
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(6-(adamantylhexyl)hexyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.02
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(adamantylhept-6-en-1-yl)piperidine-3,4,5-triol
Homo sapiens
-
above, pH and temperature not specified in the publication
0.02
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(adamantylhexyl)piperidine-3,4,5-triol
Homo sapiens
-
above, pH and temperature not specified in the publication
0.00005
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(2'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00015
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.0001
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(3'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.0001
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(4'-methyl[1,1'-biphenyl]-4-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.0002
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(5-phenylpyridin-2-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.02
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(phenanthren-9-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
-
above, pH and temperature not specified in the publication
0.0002
(2S,3R,4R,5S)-1-[5-(benzyloxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00007
(2S,3R,4R,5S)-1-[5-(cyclohexylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.001
(2S,3R,4R,5S)-1-[5-([(3R,10S,13S,17R)-10,13-dimethyl-17-[(2S)-7-methyloctan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-trio
Homo sapiens
-
pH and temperature not specified in the publication
0.00003
(2S,3R,4R,5S)-1-[5-[(1R)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00004
(2S,3R,4R,5S)-1-[5-[(1S)-1-([1,1'-biphenyl]-4-yl)ethoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.0000025
(2S,3R,4R,5S)-1-[5-[(2-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000005
(2S,3R,4R,5S)-1-[5-[(3-fluoro[1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
(2S,3R,4R,5S)-1-[5-[(4,8-dihydropyren-1-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
(2S,3R,4R,5S)-1-[5-[(5,8-dihydronaphthalen-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000025
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-2-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00007
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-3-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00002
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-2,2-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000015
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]-4,4-difluoropentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
(2S,3R,4R,5S)-1-[5-[([1,1'-biphenyl]-4-yl)methoxy]pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.0001
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-(adamantylmethoxy)pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.0025
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[(2E,6E)-3,7,10-trimethylundeca-2,6,9-trien-1-yl]oxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(5-[[3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]pentyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00025
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(6-(adamantylmethoxy)hexyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.00008
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(6-adamantyloxyhexyl)piperidine-3,4,5-triol
Homo sapiens
-
pH and temperature not specified in the publication
0.02
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-adamantylhexylpiperidine-3,4,5-triol
Homo sapiens
-
above, pH and temperature not specified in the publication
0.02
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[(6Z)-7-adamantylhept-6-en-1-yl]piperidine-3,4,5-triol
Homo sapiens
-
above, pH and temperature not specified in the publication
0.02
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-[5-[(phenanthren-9-yl)methoxy]pentyl]piperidine-3,4,5-triol
Homo sapiens
-
above, pH and temperature not specified in the publication
0.00015
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-2-carbonitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.00005
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-3-carbonitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.00015
4'-[([5-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]pentyl]oxy)methyl][1,1'-biphenyl]-4-carbonitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.02 - 0.04
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
0.01 - 0.02
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
0.02 - 0.04
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
0.005 - 0.01
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
0.001
N-adamantyl-6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0004
N-adamantyl-6-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0008
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.00075
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.0008
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(morpholin-4-yl)propan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.0008
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.0015
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.001
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(piperidin-1-yl)propan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.00005
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.0001
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]-5(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.0001
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2R,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-[(2S,3S,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4R)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3R,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-2-(4-methoxyphenoxy)acetamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]-5-(adamantylmethoxy)pentanamide
Homo sapiens
-
pH 5.2, 37°C
0.01
N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(2S,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-1-hydroxypropan-2-yl]nonanamide
Homo sapiens
-
pH 5.2, 37°C
0.0001
N-[5-(adamantan-1-yl-methoxy)-pentyl]-L-ido-1-deoxynojirimycin
Mus musculus
-
in vivo inhibition of a cell culture
0.02
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
Mus musculus
-
in vivo inhibition of a cell culture
0.04
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
Mus musculus
-
in vitro inhibition of purified enzyme
0.01
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
Mus musculus
-
in vitro inhibition of purified enzyme
0.02
N,N'-(5,5'-[2-(adamantan-1-yl)propane-1,3-diyl]bis-(oxy)bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
Mus musculus
-
in vivo inhibition of a cell culture
0.02
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
Mus musculus
-
in vivo inhibition of a cell culture
0.04
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(1-deoxynojirimycin)
Mus musculus
-
in vitro inhibition of purified enzyme
0.005
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
Mus musculus
-
in vivo inhibition of a cell culture
0.01
N,N'-(5,5'-[adamantan-1,3-diylbis(methylene)]bis(oxy)-bis(pentane-5,1-diyl))-bis(L-ido-1-deoxynojirimycin)
Mus musculus
-
in vitro inhibition of purified enzyme
0.001
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-1-deoxynojirimycin
Mus musculus
-
in vivo inhibition of a cell culture
0.005
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-1-deoxynojirimycin
Mus musculus
-
in vitro inhibition of purified enzyme
0.001
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-L-ido-1-deoxynojirimycin
Mus musculus
-
in vivo inhibition of a cell culture
0.005
N-[5-(adamantan-1-yl-ethoxy)-pentyl]-L-ido-1-deoxynojirimycin
Mus musculus
-
in vitro inhibition of purified enzyme
0.0002
N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
Mus musculus
-
in vivo inhibition of a cell culture
0.0005
N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin
Mus musculus
-
in vitro inhibition of purified enzyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
-
fluorescence assay method; fluorescence assay method
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
6.5
7.4
7.8
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
30
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
isoform A; mutants without CGT; isoform c; mutants without CGT
TREMBL
brenda
isoform B; mutants without CGT; isoform d; mutants without CGT; mutants without CGT
-
-
brenda
-
489404, 489418, 489420, 489421, 658310, 658382, 659915, 682888, 691551, 691791, 692543, 693944, 694529, 704444, 704776, 705012, 706417, 721726, 722787
-
-
brenda
-
SwissProt
brenda
-
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
GCS expression is significantly decreased in cortex of Alzheimer disease patients
brenda
-
80% of the activity in outer epidermis, 20% in lower epidermis
brenda
-
cerebellar granule cells are treated with GCS inhibitor D-threo-2-palmitoylamino-3-pyrrolidino-1-propanol which induces an increase in log-chain ceramides, loss of viability and dramatic changes in neuron/neurite morphology
brenda
-
it is shown that overexpression of the GCS gene is associated with multidrug resistance of leukemia cells
brenda
-
vinorelbine-resistant, high expression of enzyme GCS in lung cancer cells resistant to vinorelbine-induced apoptosis
brenda
-
peripheral blood cell of leukaemic patients before chemotherapy
brenda
-
U2OS-AS cell, construction of the pHA-E6S and pHA-E6AS plasmids, which respectively contain either the sense or the antisense versions of epitope-tagged E6 (HA-E6) under the control of the CMV promoter, and establishment of the U2OSE64b and U2OSE6AS cell lines by stable transfection with these plasmids has been described previously; U2OS-E6b4 cell, construction of the pHA-E6S and pHA-E6AS plasmids, which respectively contain either the sense or the antisense versions of epitope-tagged E6 (HA-E6) under the control of the CMV promoter, and establishment of the U2OSE64b and U2OSE6AS cell lines by stable transfection with these plasmids has been described previously
brenda
additional information
additional information
-
enzyme is expressed in all developmental stages
brenda
additional information
-
intraerythrocytic stages of the parasite
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
additional information
-
associated with membranes, structural integrity of the microsomal membranes is essential for activity
-
brenda
-
associated with membranes, structural integrity of the microsomal membranes is essential for activity
-
-
brenda
additional information
-
N-terminal and TM regions of the enzyme are required for localization in the Golgi apparatus
-
brenda
additional information
-
enzyme is not associated with synaptosomes and myelin
-
brenda
additional information
-
enzyme is not associated with synaptosomes and myelin
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
metabolism
physiological function
additional information
malfunction
-
In an analysis of microarray data of in a large cohort of 1681 breast tumors, there was a benefit for disease free survival for patients with tumors displaying low levels of GCS expression, especially in tumors with a positive estrogen receptor (ER) status.
malfunction
-
inhibiting UDP-glucose ceramide glycosyltransferase increases the susceptibility of p53-deficient cells, but not p53-expressing cells, to mitomycin C. Enzyme down-regulation contributes to the accumulation of ceramide in cells lacking p53
malfunction
-
when each gene function is disrupted, the brood size of the animal markedly decreases and abnormal oocytes and multinucleated embryos are formed. Knockdown of the germline expression of gene cgt-3 results in abnormal oocyte formation and abnormal embryonic cell division
malfunction
-
silencing glucosylceramide synthase expression disrupts Gb3 synthesis and selectively kills breast cancer stem cells through deactivation of c-Src/beta-catenin signaling
malfunction
-
reduced enzyme expression in the fat body causes a reduction of fat storage
malfunction
-
enzyme inhibitors affect the expression of lactosylceramide, neolacto, ganglio, and globo series glycosphingolipids in a panel of human cancer cell lines. Their cell-surface glycosphingolipid expression considerably varies among cell lines and sublethal concentrations (IC10) of both inhibitors preferentially and significantly reduce the expression of globo Gb3 glycosphingolipids in the cancer cell lines IGROV1, BG1, HT29 and T47D, whereas globo SSEA3 glycosphingolipid expression is only reduced in BG1 cells. The neolacto and ganglio glycosphingolipid series is not affected. Lactosylceramider, the precursor of all GlcCer-related glycosphingolipids, is significantly reduced only in BG1 cells treated with DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol, overview
malfunction
-
substrate reduction therapy by selectively inhibiting glucosylceramide synthase is used in treatment of Fabry disease, an X-linked inherited glycosphingolipid storage disorder, that is caused by the deficient activity of alpha-galactosidase A, which results in the lysosomal accumulation in various cell types of its glycolipid substrates, including globotriaosylceramide and lysoglobotriaosylceramide (globotriaosyl lysosphingolipid), leading to kidney, heart, and cerebrovascular disease. Kidneys of both Fabry and wild-type mice treated with enzyme inhibitor GCS Genz-682452 show reductions of galactosylceramide (about 85%) and digalactosylceramide (about 60%), a combination therapy with Genz-682452 and alpha-galactosidase A is more efficacious than either therapy alone at reducing glycosphingolipid levels in Fabry mice, phenotype, overview
malfunction
-
genetically silencing the enzyme induces apoptosis with induced ceramide accumulation, accompanied by a decrease in glucosylceramide, and inhibits Bcl-xL function. Simultaneous GCS inhibition and VNR treatment causes a decrease in Bcl-xL expression. Pharmacologically inhibiting enzyme GCS induces ceramide accumulation in vinorelbine-treated A549 and AS2 cells
malfunction
-
substrate reduction therapy by selectively inhibiting glucosylceramide synthase is used in treatment of Fabry disease, an X-linked inherited glycosphingolipid storage disorder, that is caused by the deficient activity of alpha-galactosidase A, which results in the lysosomal accumulation in various cell types of its glycolipid substrates, including globotriaosylceramide and lysoglobotriaosylceramide (globotriaosyl lysosphingolipid), leading to kidney, heart, and cerebrovascular disease. Kidneys of both Fabry and wild-type mice treated with enzyme inhibitor GCS Genz-682452 show reductions of galactosylceramide (about 85%) and digalactosylceramide (about 60%), a combination therapy with Genz-682452 and alpha-galactosidase A is more efficacious than either therapy alone at reducing glycosphingolipid levels in Fabry mice, phenotype, overview
-
metabolism
-
key enzyme for the synthesis of glycosphingolipids which plays a role in physiology and diseases for instance in drug-resistant cancers
metabolism
-
glucosylceramide synthase catalyzes the first committed step in the biosynthesis of glucosylceramide-related glycosphingolipids, pathway overview
physiological function
-
the Ugcg gene is indispensable in the gremlin in oocyte formation and early embryonic division
physiological function
-
glucosylceramide synthase expression in the fat body regulates energy metabolism in Drosophila melanogaster
physiological function
-
the enzyme catalyzes the transfer of glucose from UDP-glucose to ceramide to form glucosylceramide
physiological function
-
an increase in glucosylceramide synthase induces Bcl-xL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells, potential mechanism of glucosylceramide synthase-mediated Vinca alkaloid vinorelbine resistance in human lung adenocarcinoma cells, overview
additional information
-
the use of ethyl-2-amino-6-bromo-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate, i.e. HA14-1, as a Bcl-2 inhibitor in studies of apoptosis might produce misleading results, because HA14-1 can also affect a ceramide-mediated cell death pathway by inhibiting GlcT-1. Bcl-2 is a protein factor known to suppress apoptosis by binding and inactivating pro-apoptotic proteins such as Bax and BH3-only family proteins
additional information
-
vinorelbine works as an anticancer agent by inducing cell growth inhibition and cell apoptosis
Show AA Sequence and Transmembrane Helices (170 entries)
Please use the AA Sequence and Transmembrane Helices Search for a specific query.
Please use the AA Sequence and Transmembrane Helices Search for a specific query.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
38000
additional information
additional information
-
amino acid sequence alignment; type III membrane protein structure with N-terminal signal-anchor sequence and a long cytoplasmic tail
additional information
-
amino acid sequence alignment; type III membrane protein structure with N-terminal signal-anchor sequence and a long cytoplasmic tail
additional information
-
C- and N-terminal amino acid sequences; enzyme forms dimeric or oligomeric complexes with another protein in the Golgi membrane vivo, topology
additional information
-
C- and N-terminal amino acid sequences; enzyme forms dimeric or oligomeric complexes with another protein in the Golgi membrane vivo, topology
additional information
-
; enzyme forms dimeric or oligomeric complexes with another protein in the Golgi membrane vivo, topology
additional information
-
; enzyme forms dimeric or oligomeric complexes with another protein in the Golgi membrane vivo, topology
additional information
-
amino acid sequence of conserved D1,D2,D3,QXXRW motif
additional information
-
amino acid sequence; signal anchor domain, glycosylation site
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
DELTAFgGCS1
-
a null mutation of the FgGCS1 gene becomes resistant to antifungal defensins MsDef1, but not to MtDef4 from Medicago. It shows a significant change in the conidial morphology and displays dramatic polar growth defect, and its mycelia are resistant to cell wall degrading enzymes.GCS1 is not required for pathogenicity of Fusarium graminearum
C143A
-
site-directed mutagenesis, increased activity, reduced expression level compared to wild-type
C207A
-
site-directed mutagenesis, reduced activity, reduced inhibitory effect of N-ethylmaleimide, reduced expression level compared to wild-type
C213A
-
site-directed mutagenesis, reduced activity, reduced expression level compared to wild-type
C232A
-
site-directed mutagenesis, reduced expresssion level compared to wild-type
C290A
-
site-directed mutagenesis, reduced expression level compared to wild-type
C296A
-
site-directed mutagenesis, reduced activity, reduced expression level compared to wild-type
C343A
-
site-directed mutagenesis, enhanced activity, slightly reduced expression level compared to wild-type
C86A
-
site-directed mutagenesis, reduced activity, reduced expression level compared to wild-type
C98A
-
site-directed mutagenesis, reduced activity, reduced expression level compared to wild-type
H169A
-
26.4% activity compared to wild-type, reduced inhibition by diethyldicarbonate and increased protection by UDP-glucose
H193A
-
33.0% activity compared to wild-type, reduced inhibition by diethyldicarbonate and reduced protection by UDP-glucose
H193N
-
23.0% activity compared to wild-type, reduced inhibition by diethyldicarbonate and reduced protection by UDP-glucose
H26R
-
118.5% activity compared to wild-type, slightly enhanced inhibition by diethyldicarbonate and slightly reduced protection by UDP-glucose
H308A
-
35.2% activity compared to wild-type, slightly reduced inhibition by diethyldicarbonate and slightly reduced protection by UDP-glucose
H322N
-
49.8% activity compared to wild-type, slightly enhanced inhibition by diethyldicarbonate and slightly reduced protection by UDP-glucose
H36A
-
103.2% activity compared to wild-type, slightly enhanced inhibition by diethyldicarbonate and slightly reduced protection by UDP-glucose
additional information
additional information
-
animals lacking CGT do not synthesize glycosphingolipids, arrest growth at the first larval stage, and display defects in a subset of cells in their digestive tract, restoring CGT function in these digestive tract cells but not in a variety of other tissues is sufficient to rescue the phenotypes associated with loss of CGT function; animals lacking CGT do not synthesize glycosphingolipids, arrest growth at the first larval stage, and display defects in a subset of cells in their digestive tract, restoring CGT function in these digestive tract cells but not in a variety of other tissues is sufficient to rescue the phenotypes associated with loss of CGT function; animals lacking CGT do not synthesize glycosphingolipids, arrest growth at the first larval stage, and display defects in a subset of cells in their digestive tract, restoring CGT function in these digestive tract cells but not in a variety of other tissues is sufficient to rescue the phenotypes associated with loss of CGT function
additional information
animals lacking CGT do not synthesize glycosphingolipids, arrest growth at the first larval stage, and display defects in a subset of cells in their digestive tract, restoring CGT function in these digestive tract cells but not in a variety of other tissues is sufficient to rescue the phenotypes associated with loss of CGT function; animals lacking CGT do not synthesize glycosphingolipids, arrest growth at the first larval stage, and display defects in a subset of cells in their digestive tract, restoring CGT function in these digestive tract cells but not in a variety of other tissues is sufficient to rescue the phenotypes associated with loss of CGT function; animals lacking CGT do not synthesize glycosphingolipids, arrest growth at the first larval stage, and display defects in a subset of cells in their digestive tract, restoring CGT function in these digestive tract cells but not in a variety of other tissues is sufficient to rescue the phenotypes associated with loss of CGT function
additional information
animals lacking CGT do not synthesize glycosphingolipids, arrest growth at the first larval stage, and display defects in a subset of cells in their digestive tract, restoring CGT function in these digestive tract cells but not in a variety of other tissues is sufficient to rescue the phenotypes associated with loss of CGT function; animals lacking CGT do not synthesize glycosphingolipids, arrest growth at the first larval stage, and display defects in a subset of cells in their digestive tract, restoring CGT function in these digestive tract cells but not in a variety of other tissues is sufficient to rescue the phenotypes associated with loss of CGT function; animals lacking CGT do not synthesize glycosphingolipids, arrest growth at the first larval stage, and display defects in a subset of cells in their digestive tract, restoring CGT function in these digestive tract cells but not in a variety of other tissues is sufficient to rescue the phenotypes associated with loss of CGT function
additional information
-
loss of enzyme function by RNA interference leads to increased apoptotic cell death, conversely targeted expression of the enzyme can rescue cell death, overview
additional information
-
Ugcg flox/flox, mice that lack oligodendroglial expression of Ugcg, no influence on glycosphingolipid content in brain and myelin extracts
additional information
-
deletion mutants, lacking the first 10 or the last 8 amino acid residues, show only 4% of the wild-type activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION/commentary
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED/commentary
ORGANISM
UNIPROT
LITERATURE
cloning and transient expression in GM-95 cell line, mutant cell line containing no enzyme activity, derived from melanoma mutant cell line B16, DNA sequence determination and analysis
cloning and transient expression in GM-95 cell line, mutant cell line containing no enzyme activity, derived from melanoma mutant cell line B16, DNA sequence determination and analysis; functional expression in Escherichia coli BL21(DE3)
-
cloning from CHO cell line K1, overexpression in GM3-mutant CHO cell line Z65, DNA and amino acid sequence determination
-
cloning from rat brain genetic library and expression in Escherichia coli BL21(DE3)
-
cloning of wild-type and construction of knock-out mutant, functional expression in Saccharomyces cerevisiae strain 334, expression of wild-type leads to accumulation of beta-D-glucopyranosyl ceramides, absent in wild-type Saccharomyces cerevisiae, knock-out mutation is not lethal
-
expression of enzyme gene in antisense orientation, two-hybrid system: coexpression with the reticulon RTN family, interaction especially with RTN-1C
-
functional expression in membranes of a Pichia pastoris enzyme-deficient double-null mutant strain, also lacking sterol glucosyltransferase activity
-
functional expression of 1 isozyme in Saccharomyces cerevisiae strain 334
-
gene GlcT-1, DNA sequence determination and analysis, functional expression in enzyme-deficient GM-95 cells, expression as V5/His-tagged protein in GM95 cells
-
gene GluT-1 cloned from a human melanoma genetic library, transient overexpression in HL-60 and HL-60/ADR cells, induced resistance to DOX in HL-60 cells
-
overexpression in cancer cell lines selected for resistance to natural product chemotherapy, i.e. cell lines KB-3-1, KB-V.01, KB-V.1, KB-V1, KB-A.05, MCF-7, and MCF-7-AdrR, cell lines show different recombinant enzyme activity, which is higherin cells resistant to natural product anticancer agents, e.g. vinblastine and adriamycin, overview
-
cloning and transient expression in GM-95 cell line, mutant cell line containing no enzyme activity, derived from melanoma mutant cell line B16, DNA sequence determination and analysis
-
cloning and transient expression in GM-95 cell line, mutant cell line containing no enzyme activity, derived from melanoma mutant cell line B16, DNA sequence determination and analysis
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
after 24 h under a 42°C heat stress, GluT mRNA significantly increased to 714%; cell culture under 42°C heat stress for 24 h, increase of gene expression to 714%
-
cell culture under 42°C heat stress for 17 h, increase of gene expression to 142%
-
glucosylceramide synthase expression is enhanced in breast cancer stem cells but not in normal mammary epithelial stem cells
-
HSP70 influence on gene expression
in the absence of p53, mitomycin C treatment elicits a down-regulation of the enzyme
-
the mixed-backbone oligonucleotide MBO-asGCS considerable decreases mRNA levels in murine tumor cell lines
-
the mixed-backbone oligonucleotide MBO-asGCS decreases mRNA levels in human tumor cell lines by 65%
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
RENATURED/Commentary
ORGANISM
UNIPROT
LITERATURE
reconstitution of solubilized enzyme in detergent-free lipid vesicles
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
drug development
-
the enzyme is an attractive target for drug development both in relation to lysosomal storage disorders (in particular Gaucher disease) and type2 diabetes
medicine
molecular biology
-
glucosylceramide is essential for MsDef1-mediated growth inhibition of Fusarium graminearum, but not for its pathogenicity
pharmacology
-
enzyme might be an attractive target for malarial chemotherapy
medicine
-
potential therapeutic target for inherited sphingolipidoses such as Gaucher, Fabry, and Tay-Sachs disease
medicine
-
enzyme inhibition is a possible target for chemotherapeutic agents for a number of diseases, including cancer
medicine
-
it is shown that pharmacological lowering of glycosphingolipids, without significant reduction of ceramide, dramatically reverses insulin resistance in in vitro and in vivo models and may present a novel approach to the therapy of type 2 diabetes
medicine
-
substrate inhibition therapy with Genz-112638 represents a viable alternate approach to enzyme therapy to treat the visceral pathology in Gaucher disease
medicine
-
results show that high level of GCS in leukemia cells is associated with multidrug resistance of these cells
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.